Abstract
Patients with inflammatory skin diseases such as psoriasis and atopic dermatitis may have higher risks of malignancies compared to healthy individuals regardless of their treatments. Many of the therapies used to treat inflammatory skin diseases modulate the immune system. It is important to determine whether dermatologic therapies influence the risk of malignancies in patients with psoriasis and atopic dermatitis. However, assessing the association between dermatologic therapies and malignancies is challenging because clinical trials lack adequate population sizes and long-term follow-up needed to detect clinically important differences in malignancy rates in those receiving the medication compared to placebo. This chapter synthesizes and interprets the literature on the malignancy risks of dermatologic therapies with a focus on long-term follow-up data. Dermatologic therapies discussed in this chapter include oral systemic therapies, phototherapies, and biologic therapies. This chapter will also discuss malignancy risk in special immunosuppressed populations such as organ transplant and HIV patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AIDS:
-
Acquired immunodeficiency syndrome
- BB-UVB:
-
Broad-band ultraviolet B
- BCC:
-
Basal cell carcinoma
- CD:
-
Cluster of differentiation
- CI:
-
Confidence interval
- CMM:
-
Cutaneous malignant melanoma
- CsA:
-
Cyclosporine
- CTCL:
-
Cutaneous T-cell lymphoma
- EBV:
-
Ebstein-Barr virus
- ECG:
-
Electrocardiogram
- FDA:
-
Food and Drug Administration
- HAART:
-
Highly active antiretroviral therapy
- HHV:
-
Human Herpesvirus
- HIV:
-
Human immunodeficiency virus
- HPV:
-
Human papilloma virus
- HR:
-
Hazard ratio
- IARC:
-
International Agency for Research on Cancer
- IBD:
-
Inflammatory bowel disease
- Ig:
-
Immunoglobulin
- IL:
-
Interleukin
- IRR:
-
Incidence rate ratio
- IVIG:
-
Intravenous immunoglobulin
- MTX:
-
Methotrexate
- nbDMARDs:
-
Nonbiologic disease modifying antirheumatic drugs
- NB-UVB:
-
Narrow-band ultraviolet B
- NHL:
-
Non-Hodgkin’s lymphoma
- NIH:
-
National Institutes of Health
- NMSC:
-
Nonmelanoma skin cancer
- OR:
-
Odds ratio
- PDE:
-
Phosphodiesterase
- PSOLAR:
-
Psoriasis Longitudinal Assessment and Registry
- PUVA:
-
Psoralen-ultraviolet A
- PY:
-
Person years
- RA:
-
Rheumatoid arthritis
- RCT:
-
Randomized clinical trial
- RR:
-
Risk ratio
- SCC:
-
Squamous cell carcinoma
- SEER:
-
Surveillance, Epidemiology, and End Results Program
- SIR:
-
Standardized incidence rate
- SLE:
-
Systemic lupus erythematosus
- TNF:
-
Tumor necrosis factor
- UVA:
-
Ultraviolet A
- UVB:
-
Ultraviolet B
References
Kimball AB, et al. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. Br J Dermatol. 2014;170(2):366–73.
Hagstromer L, et al. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005;141(9):1123–7.
Scott FI, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2016;152(2):164–72.
Polesie S, et al. Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry-based cohort study. Br J Dermatol. 2017;176(6):1492–9.
Buchbinder R, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59(6):794–9.
Hoshida Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34(2):322–31.
Kamel OW, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328(18):1317–21.
Fiorentino D, et al. Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol. 2017;77(5):845–54. e5
Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol. 2006;142(9):1132–5.
Suzuki M, et al. Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis. Respirology. 2007;12(5):774–6.
Patel RV, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001–17.
Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun. 1989;2(5):723–31.
Paul CF, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120(2):211–6.
Muellenhoff MW, Koo JY. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J Dermatolog Treat. 2012;23(4):290–304.
O’Donovan P, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309(5742):1871–4.
Jiyad Z, et al. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transplant. 2016;16(12):3490–503.
Na R, et al. Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: a population-based cohort study in Australia. Br J Haematol. 2016;174(4):550–62.
Kotlyar DS, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13(5):847–858.e4; quiz e48–e50.
Beigel F, et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf. 2014;23(7):735–44.
Hagen JW, Pugliano-Mauro MA. Nonmelanoma skin cancer risk in patients with inflammatory bowel disease undergoing thiopurine therapy: a systematic review of the literature. Dermatol Surg. 2018;44(4):469–80.
Pedersen EG, et al. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. Eur J Neurol. 2014;21(3):454–8.
Wang YJ, et al. Malignancy after heart transplantation under everolimus versus mycophenolate mofetil immunosuppression. Transplant Proc. 2016;48(3):969–73.
Hsiao FY, Hsu WW. Epidemiology of post-transplant malignancy in Asian renal transplant recipients: a population-based study. Int Urol Nephrol. 2014;46(4):833–8.
Sorensen HT, et al. Use of systemic corticosteroids and risk of esophageal cancer. Epidemiology. 2002;13(2):240–1.
Sorensen HT, et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst. 2004;96(9):709–11.
Sorensen GV, et al. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res. 2012;14(1):R21.
Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol. 2005;152(3):518–23.
Kadakia KC, et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 2012;118(8):2128–37.
Cheeley J, et al. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013;68(2):247–54.
Bettoli V, Zauli S, Virgili A. Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how. J Dermatolog Treat. 2013;24(3):235–7.
Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol. 2003;49(4):644–50.
Hong WK, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315(24):1501–5.
Bhatia AK, et al. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer. 2017;123(23):4653–62.
Chen SE, et al. Isotretinoin maintenance therapy for glioblastoma: a retrospective review. J Oncol Pharm Pract. 2014;20(2):112–9.
Cash T, et al. Prolonged isotretinoin in ultra high-risk neuroblastoma. J Pediatr Hematol Oncol. 2017;39(1):e33–5.
Skroza N, et al. Isotretinoin for the treatment of squamous cell carcinoma arising on an epidermoid cyst. Dermatol Ther. 2014;27(2):94–6.
Duvic M, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581–93.
Duvic M, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–71.
Whittaker S, et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC cutaneous lymphoma task force phase III randomized clinical trial (NCT00056056). Br J Dermatol. 2012;167(3):678–87.
Pullamsetti SS, et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene. 2013;32(9):1121–34.
Suhasini AN, et al. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma. Leukemia. 2016;30(3):617–26.
Kavanaugh A, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42(3):479–88.
Reich K, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507–17.
Song GG, Lee YH. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis. Z Rheumatol. 2018;77(7):613–20.
Duvic M, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–9.
Duvic M, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009;9(6):412–6.
Olsen EA, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–15.
Piekarz RL, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–7.
Whittaker SJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–91.
Study of cancer incidence in relation to dapsone use—executive summary. [cited 2019 May 7]. http://amvif.com/government/Veterans/Dapsone/Dapsone.htm.
Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study. J Natl Cancer Inst. 1998;90(17):1278–84.
Studniberg HM, Weller P. PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol. 1993;29(6):1013–22.
Lindelof B, et al. PUVA and cancer: a large-scale epidemiological study. Lancet. 1991;338(8759):91–3.
Kimball AB, et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol. 2015;72(1):115–22.
Mariette X, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895–904.
Gottlieb AB, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011;10(3):289–300.
Hooper M, et al. Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports. Pediatr Rheumatol Online J. 2013;11(1):35.
Menter A, et al. Long-term safety and effectiveness of Adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther (Heidelb). 2017;7(3):365–81.
Leonardi C, et al. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2019;180(1):76–85.
Burmester GR, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517–24.
Lichtenstein GR, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(7):1051–63.
Torii H, et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2016;43(7):767–78.
Mackey AC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44(2):265–7.
Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–85.
Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum. 2012;64(1):21–32.
Geller S, et al. Malignancy risk and recurrence with psoriasis and its treatments: a concise update. Am J Clin Dermatol. 2018;19(3):363–75.
Dommasch ED, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–50.
Asgari MM, et al. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017;76(4):632–8.
deShazo R, Soltani-Arabshahi R, Krishnasamy S, et al. The effect of biologic therapy on non-melanoma skin cancer incidence among patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Eur Acad Dermatol Venerol. 2017.
van Lumig PP, et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol. 2015;29(4):752–60.
Papp KA, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–54.
Papp K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–14.
van de Kerkhof PC, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98. e4
Strober B, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76:432–440.e17. https://doi.org/10.1016/j.jaad.2016.09.026.
Attia A, et al. Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Investig. 2017;37(5):439–51.
Reich K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.
Amin M, et al. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1627–32.
Reich K, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88.
Papp KA, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–60.
Blauvelt A, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303.
Simpson EL, Akinlade B, Ardeleanu M. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017;376(11):1090–1.
Winthrop KL, et al. Long-term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE registry. Arthritis Care Res (Hoboken). 2018;71(8):993–1003.
Fleury I, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol. 2016;27(3):390–7.
van Vollenhoven RF, et al. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761–6.
Cheungpasitporn W, et al. The effectiveness and safety of rituximab as induction therapy in ABO-compatible non-sensitized renal transplantation: a systematic review and meta-analysis of randomized controlled trials. Ren Fail. 2015;37(9):1522–6.
Peuvrel L, et al. Melanoma and rituximab: an incidental association? Dermatology. 2013;226(3):274–8.
Uzun S, et al. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey. Int J Dermatol. 2016;55(12):1362–8.
Gupta J, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017;83(3):317–25.
Kasper S. Editorial. Int J Psychiatry Clin Pract. 2009;13(4):243–4.
Joly P, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–40.
Wang HH, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928–32.
Allen KJ, Wolverton SE. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports. J Drugs Dermatol. 2007;6(9):883–9.
Corren J, et al. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788–97.
Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. MedGenMed. 2005;7(1):27.
Long A, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–7. e4
Saini SS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(3):925.
Dhar S. Intravenous immunoglobulin in dermatology. Indian J Dermatol. 2009;54(1):77–9.
Sapir T, Shoenfeld Y. Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clin Rev Allergy Immunol. 2005;29(3):307–10.
Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med. 2013;3(7):a015677.
Engels EA, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901.
Acuna SA, et al. Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines. Am J Transplant. 2017;17(1):103–14.
Hernandez-Ramirez RU, et al. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4(11):e495–504.
Shiels MS, et al. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611–22.
WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015.
Goncalves PH, et al. Cancer prevention in HIV-infected populations. Semin Oncol. 2016;43(1):173–88.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Wu, K.K., Armstrong, A.W. (2021). Malignancy Risks of Dermatologic Therapies. In: Liu, V. (eds) Dermato-Oncology Study Guide. Springer, Cham. https://doi.org/10.1007/978-3-030-53437-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-53437-0_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-53436-3
Online ISBN: 978-3-030-53437-0
eBook Packages: MedicineMedicine (R0)